Physician profile
Akber Mohammed
NPI 1073513487
$3,210.68
in general payments reported to CMS, 2019-2025
26 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $209 · 2021: $127 · 2022: $566 · 2023: $1,658 · 2024: $48.31 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013 · Travel and Lodging: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.01 |
| Travel and Lodging | $863.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,426.30 | 2019-2023 | Leqvio |
| Janssen Pharmaceuticals, INC | $483.14 | 2019-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $237.14 | 2019-2023 | Opsumit, Uptravi |
| Boston Scientific Corporation | $191.90 | 2022-2025 | Watchman Flx, Watchman Access System, Cds - Mct/Cem Monitoring |
| Amgen INC. | $176.12 | 2019-2022 | |
| Medtronic Vascular, INC. | $91.62 | 2020 | |
| Amarin Pharma, INC. | $67.36 | 2019-2022 | |
| Shockwave Medical, INC | $57.12 | 2025 | |
| Pfizer INC. | $49.66 | 2022-2025 | |
| Livanova USA, INC. | $49.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.28 | 2022 | |
| Sanofi-Aventis U.S. LLC | $44.13 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.33 | 2022 | |
| Medtronic, INC. | $32.78 | 2024 | Closurefast |
| Terumo Medical Corporation | $31.63 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30.84 | 2019 | |
| Ge Healthcare | $21.38 | 2021 | |
| Abiomed | $20.44 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.28 | 2023 | Eliquis |
| Merck Sharp & Dohme LLC | $19.36 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.87 | 2019 | |
| Cardiovascular Systems INC. | $13.10 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2019 | |
| Astellas Pharma US INC | $12.46 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.71 | 2019 | |
| Gilead Sciences, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akber Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.